Analysed ASCLETIS PHARMA INC (ASCLF:OTCMKTS) News Sources
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
02-02-2026
yahoo.com
Sagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim Conference
15-02-2026
marketbeat.com
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
10-08-2026
yahoo.com
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
17-08-2026
marketbeat.com
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
30-08-2026
yahoo.com
Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
07-09-2026
yahoo.com
What is the current price of ASCLETIS PHARMA INC (ASCLF:OTCMKTS)?
The current price of ASCLETIS PHARMA INC (ASCLF:OTCMKTS) is $1.3.
ASCLETIS PHARMA INC (ASCLF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of ASCLETIS PHARMA INC (ASCLF:OTCMKTS) since the previous trading day is $0.02.
ASCLETIS PHARMA INC (ASCLF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of ASCLETIS PHARMA INC (ASCLF:OTCMKTS) since the previous trading day is 1.5625%.
What is the most recent average sentiment score for ASCLETIS PHARMA INC (ASCLF:OTCMKTS)?
The most recent average sentiment score for ASCLETIS PHARMA INC (ASCLF:OTCMKTS) is 71 out of 100.
What is the most recent average sentiment for ASCLETIS PHARMA INC (ASCLF:OTCMKTS)?
The most recent sentiment for ASCLETIS PHARMA INC (ASCLF:OTCMKTS) is .
SEC-8K** Filing Available For ASCLETIS PHARMA INC (ASCLF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.